Lexeo Therapeutics Inc LXEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $4.24
- Day Range
- $4.17–4.43
- 52-Week Range
- $3.63–10.99
- Bid/Ask
- $4.17 / $4.22
- Shares Outstanding
- 78.52M
- Market Cap
- $329.79M
- Volume/Avg
- 137,831 / 847,838
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 59
- Website
- https://www.lexeotx.com
Valuation
|
Metric
|
LXEO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LXEO
|
|---|---|
Quick Ratio | 13.61 |
Current Ratio | 14.16 |
Interest Coverage | −515.90 |
Quick Ratio
LXEO
Profitability
|
Metric
|
LXEO
|
|---|---|
Return on Assets (Normalized) | −39.55% |
Return on Equity (Normalized) | −46.23% |
Return on Invested Capital (Normalized) | −47.97% |
Return on Assets
LXEO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Vkkcrwzm | Krxlcr | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Chcknqtm | Vmntns | $65B | |||
| argenx SE ADR
ARGX
| Ccdmnrwr | Fyvk | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gsthgrtw | Rcdssx | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Llyxzppf | Hjqjdy | $25B | |||
| BioNTech SE ADR
BNTX
| Xhnhmrcrj | Xqsl | $22B | |||
| Incyte Corp
INCY
| Kwxbmbkb | Glzx | $21B | |||
| Moderna Inc
MRNA
| Jvsjhqzl | Zjwc | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Yvkvyljzc | Jvqc | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Klgdrpfr | Kly | $13B |
United States